More recently, tumor-selective expression of exogenous NIS has been proposed as a new strategy to deliver high absorbed doses selectively to tumors using radioiodine therapy for non-thyroidal cancers [4, 5]. This evidence concerns the gene SLC5A5 and thyroid cancer.